We present herein the first visible-light-driven hydrocarboxylation as well as carbocarboxylation of alkynes using CO2 via an iridium/cobalt dual catalysis. Such transformations provide access to various pharmaceutically important heterocycles in a one-pot procedure from readily available alkynes. Coumarins, 2-quinolones, and 2-benzoxepinones were directly accessed through a one-pot alkyne hydrocarboxylation/alkene
我们在此展示了第一个可见光驱动的烃羧化以及通过铱/钴双催化使用 CO2 的炔烃的羧化。这种转化提供了通过一锅法从容易获得的炔烃获得各种药学上重要的杂环的途径。通过一锅炔烃加氢羧化/烯烃异构化/环化序列直接获得香豆素、2-喹诺酮和 2-苯并氧杂环酮,其中 Ir 光催化剂起到双重作用,促进炔烃加氢羧化中的单电子转移和随后的能量转移烯烃异构化。此外,前所未有的钴羧化/酰基迁移级联使炔双官能化能够高效引入γ-羟基丁烯内酯。
Synthesis of 3-Alkoxymethylcoumarin from 3-Cyanochromene via a Novel Intermediate 2-Phenylimino-3-alkoxymethylchromene
作者:Jui-Chi Tsai、Sie-Rong Li、Michael Y. Chiang、Lian-Yeu Chen、Po-Yuan Chen、Yi-Fang Lo、Chen-Hao Wang、Chun-Nan Lin、Eng-Chi Wang
DOI:10.1021/jo9015634
日期:2009.11.20
method for the synthesis of 3-alkoxymethylcoumarin is described. From the reaction of 3-cyanochromene with an alkoxide and arylamine in THF, (Z)-2-phenylimino-3-alkoxymethylchromene was obtained as a novelintermediate via an isomerization of the double bond, a 1,2-addition of alkoxide, a Michael-type addition of aniline, an another isomerization of double bond and an elimination of ammonia. Subsequently
The present invention relates to a compound of the general formula (1). The compound of formula (1) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
The present invention relates to a compound of the general formula (1). The compound of formula (1) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.